Compare Stocks: ARVN, BHVN, ABCL, and STOK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.36B	1.2	8.99 million shs	12.33 million shs
ARVN Arvinas	$8.97 -0.4%	$8.16	$6.95 ▼ $14.51	$581.33M	1.71	913,368 shs	461,094 shs
BHVN Biohaven	$14.66 -1.3%	$14.32	$7.48 ▼ $18.57	$2.24B	1.26	1.91 million shs	1.24 million shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.69	$16.90 ▼ $40.22	$2.02B	1.2	812,414 shs	495,115 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+3.74%	+64.21%	+68.84%	+178.24%	+148.69%
ARVN Arvinas	-0.44%	+2.51%	+8.33%	-1.21%	+26.52%
BHVN Biohaven	-1.43%	-0.05%	-1.29%	+67.71%	+1.76%
STOK Stoke Therapeutics	-0.13%	-4.40%	+4.55%	+3.96%	+84.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.38 +3.7%	$6.65	$2.74 ▼ $11.50	$3.36B	1.2	8.99 million shs	12.33 million shs
ARVN Arvinas	$8.97 -0.4%	$8.16	$6.95 ▼ $14.51	$581.33M	1.71	913,368 shs	461,094 shs
BHVN Biohaven	$14.66 -1.3%	$14.32	$7.48 ▼ $18.57	$2.24B	1.26	1.91 million shs	1.24 million shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.69	$16.90 ▼ $40.22	$2.02B	1.2	812,414 shs	495,115 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+3.74%	+64.21%	+68.84%	+178.24%	+148.69%
ARVN Arvinas	-0.44%	+2.51%	+8.33%	-1.21%	+26.52%
BHVN Biohaven	-1.43%	-0.05%	-1.29%	+67.71%	+1.76%
STOK Stoke Therapeutics	-0.13%	-4.40%	+4.55%	+3.96%	+84.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	12.77% Upside
ARVN Arvinas	2.45	Hold	$14.17	57.93% Upside
BHVN Biohaven	2.65	Moderate Buy	$21.75	48.33% Upside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	37.51% Upside

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, ABCL, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00
8/11/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/10/2026	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $21.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$66.17M	52.73	N/A	N/A	$2.92 per share	3.90
ARVN Arvinas	$316.70M	1.83	N/A	N/A	$8.71 per share	1.03
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.08 per share	N/A
STOK Stoke Therapeutics	$27.59M	73.14	N/A	N/A	$5.36 per share	5.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	N/A
ARVN Arvinas	-$80.80M	$0.10	89.71	N/A	N/A	2.94%	1.91%	1.29%	N/A
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	N/A
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)

Latest ARVN, BHVN, ABCL, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
ARVN Arvinas	N/A	7.91	7.91
BHVN Biohaven	21.23	4.73	7.41
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ARVN Arvinas	95.19%
BHVN Biohaven	88.78%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
ARVN Arvinas	7.30%
BHVN Biohaven	13.80%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable

ARVN, BHVN, ABCL, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Purchases 55,672 Shares of Stoke Therapeutics, Inc. $STOK

August 9, 2026 | marketbeat.com

Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A.

August 9, 2026 | marketbeat.com

Research Analysts Offer Predictions for STOK Q3 Earnings

August 8, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

HC Wainwright Has Bearish Forecast for STOK FY2029 Earnings

August 7, 2026 | americanbankingnews.com

Q3 EPS Estimates for Stoke Therapeutics Cut by HC Wainwright

August 6, 2026 | marketbeat.com

Barry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

August 6, 2026 | insidertrades.com

Wedbush Increases Stoke Therapeutics (NASDAQ:STOK) Price Target to $40.00

August 6, 2026 | americanbankingnews.com

Canaccord Genuity Group Issues Pessimistic Forecast for Stoke Therapeutics (NASDAQ:STOK) Stock Price

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital

August 6, 2026 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

August 5, 2026 | marketbeat.com

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

August 5, 2026 | seekingalpha.com

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

August 5, 2026 | finance.yahoo.com

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

August 5, 2026 | theglobeandmail.com

Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary

August 5, 2026 | finance.yahoo.com

FY2029 Earnings Estimate for STOK Issued By HC Wainwright

August 5, 2026 | marketbeat.com

Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK

August 5, 2026 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Guggenheim

August 4, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings

August 4, 2026 | 247wallst.com

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

August 4, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, ABCL, and STOK Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.38 +0.41 (+3.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$11.40 +0.02 (+0.18%)

As of 08/14/2026 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Arvinas NASDAQ:ARVN

$8.97 -0.04 (-0.44%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$8.93 -0.04 (-0.48%)

As of 08/14/2026 07:43 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Biohaven NYSE:BHVN

$14.66 -0.19 (-1.26%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$14.94 +0.28 (+1.88%)

As of 08/14/2026 07:56 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Stoke Therapeutics NASDAQ:STOK

$31.27 -0.04 (-0.13%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$31.28 +0.02 (+0.05%)

As of 08/14/2026 07:34 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, ABCL, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, BHVN, ABCL, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, BHVN, ABCL, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, ABCL, and STOK Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, BHVN, ABCL, and STOK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, BHVN, ABCL, and STOK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, BHVN, ABCL, and STOK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, BHVN, ABCL, and STOK Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools